Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NantKwest

- PMLiVE

Keytruda combo outshines Opdivo in kidney cancer

BMS also on the backfoot after Nektar data release

- PMLiVE

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

Partners to co-develop novel bifunctional fusion protein

- PMLiVE

EU approval for Opdivo combo in renal cell cancer

BMS one step ahead of rivals

- PMLiVE

Chinese biotechs aim PD-L1 antibody at hepatitis B

Cancer therapies could help boost patient's immune system

- PMLiVE

AZ still sees route to approval for Imfinzi in MYSTIC trial

New analysis shows opportunity in NSCLC

Porterhouse Medical is raising awareness for pancreatic cancer, here’s why…

Porterhouse Medical Group

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer

Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Porterhouse Medical Group

- PMLiVE

Soon-Shiong presents first data on cancer memory vaccine at SITC

Novel cocktail shows modest gains in prostate cancer

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links